AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12565115 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil bolus at 0.5 microg kg(‐1) started after tourniquet inflation (Group 3, n=4)
Number of subjects: 16
Study 10341686 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution ultrasound (US) analysis of the liver surface
Number of subjects: 100
Study 10341686 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution ultrasound (US) analysis of the liver surface (including non-diagnostic cases as true-positive and false-positive)
Number of subjects: 100
Study 7593871 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional expression group (writing about personal traumatic events)
Number of subjects: 40
Study 7593871 — intervention group
Group type: COMPARATOR
Intervention: Control group (writing about control topics)
Number of subjects: 40
Study 7593871 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional expression group
Number of subjects: 40
Study 7593871 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 2034482 — intervention group
Group type: COMPARATOR
Intervention: Exchange transfusion only (24%)
Number of subjects: 224
Study 31580144 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline data collection
Number of subjects: 0
Study 31580144 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 30346860 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg OD at 8:00 AM
Number of subjects: 12
Study 30346860 — intervention group
Group type: COMPARATOR
Intervention: 80 mg OD at 8:00 PM
Number of subjects: 12
Study 30346860 — intervention group
Group type: COMPARATOR
Intervention: 40 mg BID at 8:00 AM and PM
Number of subjects: 12
Study 27654837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 31
Study 26410579 — intervention group
Group type: COMPARATOR
Intervention: Anodal tDCS + sham tsDCS (group 1)
Number of subjects: 30
Study 26410579 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS + cathodal tsDCS (group 2)
Number of subjects: 30
Study 26410579 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS + cathodal tsDCS (group 3)
Number of subjects: 30
Study 23357031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol at BAC levels of 0.5g/L and 0.9g/L
Number of subjects: 20
Study 23357031 — intervention group
Group type: COMPARATOR
Intervention: Placebo drinks and placebo pills
Number of subjects: 20
Study 20638188 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group scoring system for intracerebral control (IC)
Number of subjects: 1797
Study 20638188 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation group scoring system for intracerebral control (IC)
Number of subjects: 1797
Study 20638188 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group scoring system for overall survival (OS)
Number of subjects: 1797
Study 20638188 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation group scoring system for overall survival (OS)
Number of subjects: 1797
Study 19756426 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol suppositories
Number of subjects: 100
Study 19756426 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 100
Study 17503102 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 50
Study 17503102 — intervention group
Group type: COMPARATOR
Intervention: Placebo-CPAP
Number of subjects: 50
Study 15467327 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 inhalation
Number of subjects: 10
Study 15467327 — intervention group
Group type: COMPARATOR
Intervention: Air breathing (control)
Number of subjects: 10
Study 11550730 — intervention group
Group type: COMPARATOR
Intervention: Standard contingency management (abstinence group)
Number of subjects: 95
Study 11550730 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency designed to increase contact with reinforcers (shaping group)
Number of subjects: 95
Study 11550730 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaping group
Number of subjects: 95
Study 11550730 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating‐value vouchers
Number of subjects: 95
Study 9570192 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormone replacement therapy
Number of subjects: 100
Study 9570192 — intervention group
Group type: COMPARATOR
Intervention: No substitution (control)
Number of subjects: 100
Study 8072054 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 100
Study 8072054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8072054 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol and Placebo
Number of subjects: 100
Study 3054626 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg bid
Number of subjects: 36
Study 3054626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31904760 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (60 g/day) with high-fiber wheat bran (30 g fiber/day)
Number of subjects: 65
Study 31904760 — intervention group
Group type: COMPARATOR
Intervention: Whey protein (60 g/day) with low-fiber refined wheat (10 g fiber/day)
Number of subjects: 65
Study 31904760 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin with high-fiber wheat bran (30 g fiber/day)
Number of subjects: 65
Study 31904760 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin with low-fiber refined wheat (10 g fiber/day)
Number of subjects: 65
Study 31904760 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (60 g/day)
Number of subjects: 65
Study 28474319 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy (LSG)
Number of subjects: 150
Study 28474319 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y Gastric Bypass (LRYGB)
Number of subjects: 150
Study 25117433 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball-carry group (BC; n = 12)
Number of subjects: 24
Study 25117433 — intervention group
Group type: COMPARATOR
Intervention: No-ball-carry group (NBC; n = 12)
Number of subjects: 24
Study 23523423 — intervention group
Group type: EXPERIMENTAL
Intervention: 3× loupe magnified inguinal varicocelectomy (Group A & B1)
Number of subjects: 173
Study 23523423 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (Group B2)
Number of subjects: 173
Study 23523423 — intervention group
Group type: EXPERIMENTAL
Intervention: 3× loupe magnified inguinal varicocelectomy (Group B1)
Number of subjects: 173
Study 21443316 — intervention group
Group type: EXPERIMENTAL
Intervention: EC-enhancing intervention (15-hour group format intervention with a 4-week e-mail follow-up)
Number of subjects: 132
Study 21443316 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study 18205902 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA
Number of subjects: 68
Study 18205902 — intervention group
Group type: COMPARATOR
Intervention: Paper
Number of subjects: 68
Study 16989679 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine interventions (specifics not provided)
Number of subjects: 0
Study 12706935 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (125 or 250 mg twice daily)
Number of subjects: 85
Study 11022397 — intervention group
Group type: COMPARATOR
Intervention: Tropicamide (20 microL, 0.01%) administered to one eye and placebo to the other.
Number of subjects: 19
Study 11022397 — intervention group
Group type: COMPARATOR
Intervention: Tropicamide (20 microL, 0.01%) followed by pilocarpine (20 microL, 0.1%) to one eye and placebo to the other.
Number of subjects: 19
Study 11022397 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine (0.5 mg, intravenously) administered in separate sessions.
Number of subjects: 19
Study 8612392 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin 300 mg daily
Number of subjects: 60
Study 8612392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1596225 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluoropropane gas (group 1)
Number of subjects: 265
Study 1596225 — intervention group
Group type: COMPARATOR
Intervention: Silicone oil (group 1)
Number of subjects: 265
Study 1596225 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluoropropane gas (group 2)
Number of subjects: 265
Study 1596225 — intervention group
Group type: COMPARATOR
Intervention: Silicone oil (group 2)
Number of subjects: 265
Study 1596225 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluoropropane gas (group 1, follow-up ≥ 18 months)
Number of subjects: 265
Study 1596225 — intervention group
Group type: COMPARATOR
Intervention: Silicone oil (group 1, follow-up ≥ 18 months)
Number of subjects: 265
Study 6692384 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrazine sulfate (60 mg, 3 times/day for 30 days)
Number of subjects: 38
Study 6692384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 6692384 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrazine sulfate
Number of subjects: 38
Study 29122709 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (10mg daily for 3 days) followed by vaginal misoprostol
Number of subjects: 78
Study 29122709 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol alone
Number of subjects: 78
Study 27113048 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg per day)
Number of subjects: 42
Study 27113048 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol succinate (100 mg per day)
Number of subjects: 42
Study 27113048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 23707383 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT), n=50
Number of subjects: 98
Study 23707383 — intervention group
Group type: COMPARATOR
Intervention: Waiting List (WL) control, n=48
Number of subjects: 98
Study 21987516 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional abuse with physical and/or sexual abuse
Number of subjects: 1293
Study 21987516 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional abuse alone
Number of subjects: 1293
Study 21987516 — intervention group
Group type: COMPARATOR
Intervention: No abuse
Number of subjects: 1293
Study 20886797 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture articles
Number of subjects: 583
Study 18545180 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-second resting interval
Number of subjects: 10
Study 18545180 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-second resting interval
Number of subjects: 10
Study 18545180 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-second resting interval
Number of subjects: 10
Study 18545180 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-second resting interval
Number of subjects: 10
Study 15877550 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercisers (reporting > or = 1,000 kcal/wk of exercise activity)
Number of subjects: 3075
Study 15877550 — intervention group
Group type: COMPARATOR
Intervention: Inactive persons (reporting < 1,000 kcal/wk of exercise activity and < 2,719 kcal/wk of total physical activity)
Number of subjects: 3075
Study 15877550 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle active (reporting < 1,000 kcal/wk of exercise activity and > or = 2,719 kcal/wk of total physical activity)
Number of subjects: 3075
Study 12821232 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 0.5 mg/day
Number of subjects: 593
Study 12821232 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 593
Study 10826403 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 to 10 mg daily)
Number of subjects: 24
Study 8652214 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hypertonic saline (HS)
Number of subjects: 10
Study 8652214 — intervention group
Group type: COMPARATOR
Intervention: 0.9% isotonic saline (IS)
Number of subjects: 10
Study 1509383 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrozepin (22 persons)
Number of subjects: 45
Study 1509383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranisan (23 persons)
Number of subjects: 45
Study 1509383 — intervention group
Group type: COMPARATOR
Intervention: Control (15 subjects)
Number of subjects: 45
Study 6382981 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 73
Study 6382981 — intervention group
Group type: COMPARATOR
Intervention: metrizamide
Number of subjects: 73
Study 30570309 — intervention group
Group type: EXPERIMENTAL
Intervention: CBTsa (Cognitive Behavioral Therapy for social activation)
Number of subjects: 99
Study 30570309 — intervention group
Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 99
Study 30570309 — intervention group
Group type: EXPERIMENTAL
Intervention: CBTsa
Number of subjects: 99
Study 30570309 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 99
Study 27269367 — intervention group
Group type: EXPERIMENTAL
Intervention: Good adherence to the Mediterranean diet
Number of subjects: 1643
Study 27269367 — intervention group
Group type: COMPARATOR
Intervention: Higher intake of sweets, sugar‐sweetened beverages, and fast foods
Number of subjects: 1643
Study 27269367 — intervention group
Group type: COMPARATOR
Intervention: Vegetable intake
Number of subjects: 1643
Study 27269367 — intervention group
Group type: COMPARATOR
Intervention: KIDMED score
Number of subjects: 1643
Study 27269367 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure
Number of subjects: 1643
Study 26016955 — intervention group
Group type: EXPERIMENTAL
Intervention: Grief intervention treatment group
Number of subjects: 40
Study 26016955 — intervention group
Group type: COMPARATOR
Intervention: Usual standard care control group
Number of subjects: 40
Study 23444920 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human antithrombin
Number of subjects: 60
Study 23444920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21276961 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin monotherapy (48 weeks; n=31)
Number of subjects: 54
Study 21276961 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (n=23)
Number of subjects: 54
Study 19968385 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple therapy
Number of subjects: 254
Study 16520433 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 369
Study 16520433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study 12743670 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine hydrochloride 250 mg alone
Number of subjects: 24
Study 12743670 — intervention group
Group type: COMPARATOR
Intervention: Quinine hydrochloride 250 mg with four other CYP probe drugs
Number of subjects: 24
Study 12743670 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine hydrochloride 250 mg with ketoconazole
Number of subjects: 24
Study 12743670 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine hydrochloride 250 mg with fluvoxamine
Number of subjects: 24
Study 11368286 — intervention group
Group type: EXPERIMENTAL
Intervention: IV levosimendan
Number of subjects: 0
Study 9337806 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic health exam including blood pressure testing, cholesterol screening, and baseline ECG
Number of subjects: 0
Study 7524040 — intervention group
Group type: EXPERIMENTAL
Intervention: HOME Inventory (IT-HOME) at 12 months
Number of subjects: 0
Study 7524040 — intervention group
Group type: EXPERIMENTAL
Intervention: HOME Inventory (EC-HOME) at 36 months
Number of subjects: 0
Study 7524040 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of the home environment (measured by HOME Inventory)
Number of subjects: 0
Study 3302868 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (C)
Number of subjects: 47
Study 3302868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin plus Tobramycin (C + T)
Number of subjects: 47
Study 29338584 — intervention group
Group type: EXPERIMENTAL
Intervention: βHB salts (0.38 g kg body mass‐1) in plain water (3.8 mL kg body mass‐1)
Number of subjects: 19
Study 29338584 — intervention group
Group type: COMPARATOR
Intervention: plain water (3.8 mL kg body mass‐1) (CON)
Number of subjects: 19
Study 26913621 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling (TC)
Number of subjects: 64
Study 26913621 — intervention group
Group type: COMPARATOR
Intervention: Self-directed physical activity education (EC)
Number of subjects: 64
Study 25567121 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance strength training coupled with falls prevention education
Number of subjects: 210
Study 25567121 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement strategy training combined with falls prevention education
Number of subjects: 210
Study 25567121 — intervention group
Group type: COMPARATOR
Intervention: Life-skills information (control)
Number of subjects: 210
Study 24162833 — intervention group
Group type: COMPARATOR
Intervention: Direct cardioversion (group A)
Number of subjects: 110
Study 24162833 — intervention group
Group type: EXPERIMENTAL
Intervention: Further ablation of subsequent atrial tachycardias to sinus rhythm (group B)
Number of subjects: 110
Study 21368750 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg b.i.d. for 9 weeks
Number of subjects: 12
Study 21368750 — intervention group
Group type: EXPERIMENTAL
Intervention: amiloride
Number of subjects: 12
Study 21368750 — intervention group
Group type: EXPERIMENTAL
Intervention: urinary α-ENaC
Number of subjects: 12
Study 21368750 — intervention group
Group type: COMPARATOR
Intervention: furosemide
Number of subjects: 12
Study 19451669 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored advice
Number of subjects: 302
Study 19451669 — intervention group
Group type: COMPARATOR
Intervention: Generic advice
Number of subjects: 302
Study 19451669 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored advice with action plan
Number of subjects: 302
Study 16490809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE) 10 mg coadministered with CyA (75-150 mg twice a day)
Number of subjects: 0
Study 16490809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE) 10 mg with CyA
Number of subjects: 0
Study 16490809 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 0
Study 14508021 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo group (received information about pain relieving injection)
Number of subjects: 59
Study 14508021 — intervention group
Group type: COMPARATOR
Intervention: Nocebo group (received information about pain increasing injection)
Number of subjects: 59
Study 14508021 — intervention group
Group type: COMPARATOR
Intervention: Natural History group (received no information and no injection)
Number of subjects: 59
Study 11191179 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 0.5 mg
Number of subjects: 16
Study 11191179 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 2.5 mg
Number of subjects: 16
Study 11191179 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 5.0 mg
Number of subjects: 16
Study 11191179 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 16
Study 11191179 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (all doses)
Number of subjects: 16
Study 9197295 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% xenon
Number of subjects: 30
Study 9197295 — intervention group
Group type: COMPARATOR
Intervention: 60% N2O + 0.5% isoflurane
Number of subjects: 30
Study 9197295 — intervention group
Group type: COMPARATOR
Intervention: 60% N2O + 0.70% sevoflurane
Number of subjects: 30
Study 1307893 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside measurement of activated clotting time (ACT) by nursing staff with management by protocol.
Number of subjects: 254
Study 1307893 — intervention group
Group type: COMPARATOR
Intervention: Independent medical decisions by resident medical staff.
Number of subjects: 254
Study 3095507 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol for ICP elevations greater than 25 mm Hg
Number of subjects: 80
Study 3095507 — intervention group
Group type: COMPARATOR
Intervention: Empirical mannitol therapy irrespective of ICP readings
Number of subjects: 80
Study 29332056 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous ozone injection alone (Control)
Number of subjects: 47
Study 29332056 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ozone injection and percutaneous microdiscectomy (Treatment)
Number of subjects: 47
Study 27476806 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable second-generation antipsychotic
Number of subjects: 305
Study 27476806 — intervention group
Group type: COMPARATOR
Intervention: Oral second-generation antipsychotic
Number of subjects: 305
Study 27476806 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent relapses
Number of subjects: 305
Study 27476806 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable medication administration schedule
Number of subjects: 305
Study 25473212 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraFill® (porcine collagen filler)
Number of subjects: 61
Study 25473212 — intervention group
Group type: COMPARATOR
Intervention: KOKEN® (bovine collagen filler)
Number of subjects: 61
Study 22324458 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized assessment and evidence-based treatment for urinary incontinence
Number of subjects: 225
Study 20399995 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation A (valsartan 160 mg)
Number of subjects: 18
Study 20399995 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation B (valsartan 160 mg)
Number of subjects: 18
Study 20399995 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (valsartan 160 mg)
Number of subjects: 18
Study 18512043 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycaemia (blood glucose level at 5 mmol/l)
Number of subjects: 7
Study 18512043 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (blood glucose level at 11 mmol/l)
Number of subjects: 7
Study 18512043 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycaemia
Number of subjects: 7
Study 18512043 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia
Number of subjects: 7
Study 17310949 — intervention group
Group type: EXPERIMENTAL
Intervention: DNAase treatment
Number of subjects: 0
Study 17310949 — intervention group
Group type: COMPARATOR
Intervention: Antibacterial therapy
Number of subjects: 0